主要研究方向：病毒性肝病免疫发病机制和治疗。先后承担国家十二五、十三五病毒性肝炎重大专项子课题、江苏省科技厅临床科技专项、江苏省自然基金、中华医学会临床医学科研专项等课题，发表学术论文90余篇，获江苏省医学新技术引进奖及徐州市科技进步奖3项。

现为亚太医学生物免疫学会肝病学分会常务委员全国疑难和重症肝病攻关协作组委员，中国医师协会整合医学感染预防和控制委员会委员，江苏省医学会感染病学分会常务委员兼新发传染病和感染病学组副组长 江苏省医学会肝脏病学分会委员，江苏省医师协会感染病分会委员，徐州市感染病学分会副主任委员，徐州市免疫学会副会长及徐医附院疑难发热疾病多学科诊疗MDT团队负责人。

近5年发表文章（通讯作者）

1）Li RQ, Li XQ, Zhao J, Meng FD, Yao C, Bao ES, Sun N, Chen X, Cheng WP, Hua H, Li XY, Wang B, Wang H, Pan XC*, You HJ*, Yang J*, Ikezoe T. Mitochondrial STAT3 exacerbates LPS-induced sepsis by driving CPT1a-mediated fatty acid oxidation. Theranostics, 2022,12(2):976-997

2) Wang JY; Li C; Fu JJ; Wang X; Feng X; Pan XC* Tim‐3 regulates inflammatory cytokine expression and Th17 cel response induced by monocytes from patients with chronic hepatitis B.  Scand J of immunology, 2019, 89(5).e12755

3) Shan B; Wang JY; Wang X; Fu JJ; Li L; Pan XC*; Li JJ; Tang XT. VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg‐positive chronic hepatitis B patients treated with pegylated interferon.  J of Med Virol, 2018, 91(5): 765-774. 

4) Wang X; Xu ZQ; Fu JJ; Cheng LW; Li Y; Li L; Pan XC * . Role of interleukin-21 and interleukin-21 receptor polymorphisms in the treatment of HBeAg-positive chronic hepatitis B patients with peginterferon. Medicine, 2018, 97(23):e10891   

5) Wang Q, Xu ZQ, Fu JJ, Pan XC*. Hepatitis B virus reactivation recurred after the cessation of entecavir in an allogenetic hematopoietic stem cell transplantation patient. Clin Res Hepatol Gastroenterol.2017;41(4):e48-e50.